{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/13959"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/13959","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"CATECHOLAMINE-REGULATED PROTEIN 40 IN PARKINSON’S DISEASE","abstract":"<p>Parkinson’s disease (PD) is a complex neurodegenerative movement disorder involving protein misfolding, mitochondrial dysfunction, and oxidative stress. The current dissertation, motivated by a lack of valid biomarkers and sustainable therapies, examined the potential application of a novel target for therapeutics and diagnostics of PD — the multifunctional, heat-shock like protein Catecholamine-Regulated Protein 40 (CRP40). The goal of this program of research was to elucidate further the implications of CRP40 in PD using a variety of molecular biology, bioinformatics, and clinical approaches through integrative collaborations with academia, government, and industry partners to translate scientific findings into real world solutions. Chapters 2 and 3 explored the potential therapeutic use and structure-function relationships of CRP40 through elucidating the smallest functional piece of this protein that was six times smaller, and validating a negative control for these experiments (Heat-Shock Protein 47). These initiatives could eventually lead to a small drug that could cross the blood-brain barrier and be targeted to the specific brain regions affected in PD. Chapter 4 examined the potential mechanisms of CRP40, and suggested that this protein may protect neurons from oxidative stress, maintain energy levels, and mitochondrial homeostasis, with important future implications for a variety of disorders. Finally, Chapter 5 presented compelling evidence for the potential use of CRP40 as a valid biomarker for early detection of PD and monitoring of disease progression. Overall, findings suggest that CRP40 may be a critical target for future breakthroughs in the diagnosis and treatment of PD.</p>","abstract_html":"&lt;p&gt;Parkinson’s disease (PD) is a complex neurodegenerative movement disorder involving protein misfolding, mitochondrial dysfunction, and oxidative stress. The current dissertation, motivated by a lack of valid biomarkers and sustainable therapies, examined the potential application of a novel target for therapeutics and diagnostics of PD — the multifunctional, heat-shock like protein Catecholamine-Regulated Protein 40 (CRP40). The goal of this program of research was to elucidate further the implications of CRP40 in PD using a variety of molecular biology, bioinformatics, and clinical approaches through integrative collaborations with academia, government, and industry partners to translate scientific findings into real world solutions. Chapters 2 and 3 explored the potential therapeutic use and structure-function relationships of CRP40 through elucidating the smallest functional piece of this protein that was six times smaller, and validating a negative control for these experiments (Heat-Shock Protein 47). These initiatives could eventually lead to a small drug that could cross the blood-brain barrier and be targeted to the specific brain regions affected in PD. Chapter 4 examined the potential mechanisms of CRP40, and suggested that this protein may protect neurons from oxidative stress, maintain energy levels, and mitochondrial homeostasis, with important future implications for a variety of disorders. Finally, Chapter 5 presented compelling evidence for the potential use of CRP40 as a valid biomarker for early detection of PD and monitoring of disease progression. Overall, findings suggest that CRP40 may be a critical target for future breakthroughs in the diagnosis and treatment of PD.&lt;/p&gt;","abstract_has_math":false,"creators":["Lubarda, Jovana"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Neuroscience","school":null,"contributors":[],"advisors":["Gabriele, Joseph","Mishra, Ram","Doering, Laurie"],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-04","date_published":"2014-04","updated_at":"2026-11-18T19:37:30Z","subjects":["Catecholamine-regulated protein 40","Parkinson’s disease","movement disorder","protein cloning","oxidative stress","Diagnosis","Medical Biochemistry","Medical Molecular Biology","Nervous System Diseases","Therapeutics"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/18778"],"render_values":[{"text":"https://doi.org/10.71548/18778","href":"https://doi.org/10.71548/18778","code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/8791","9858","5060668"],"render_values":[{"text":"opendissertations/8791","href":null,"code":true},{"text":"9858","href":null,"code":true},{"text":"5060668","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/13959","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/13959","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F13959","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Gabriele, Joseph","Mishra, Ram","Doering, Laurie"]},{"key":"dc:contributor.department","label":"Department","values":["Neuroscience"]},{"key":"dc:creator","label":"Author","values":["Lubarda, Jovana"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-06-18T17:05:42Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-06-18T17:05:42Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2014-02-04"]},{"key":"dc:date.issued","label":"Date","values":["2014-04"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Catecholamine-regulated protein 40","Parkinson’s disease","movement disorder","protein cloning","oxidative stress","Diagnosis","Medical Biochemistry","Medical Molecular Biology","Nervous System Diseases","Therapeutics"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/8791","9858","5060668"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/13959","https://doi.org/10.71548/18778"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p>Parkinson’s disease (PD) is a complex neurodegenerative movement disorder involving protein misfolding, mitochondrial dysfunction, and oxidative stress. The current dissertation, motivated by a lack of valid biomarkers and sustainable therapies, examined the potential application of a novel target for therapeutics and diagnostics of PD — the multifunctional, heat-shock like protein Catecholamine-Regulated Protein 40 (CRP40). The goal of this program of research was to elucidate further the implications of CRP40 in PD using a variety of molecular biology, bioinformatics, and clinical approaches through integrative collaborations with academia, government, and industry partners to translate scientific findings into real world solutions. Chapters 2 and 3 explored the potential therapeutic use and structure-function relationships of CRP40 through elucidating the smallest functional piece of this protein that was six times smaller, and validating a negative control for these experiments (Heat-Shock Protein 47). These initiatives could eventually lead to a small drug that could cross the blood-brain barrier and be targeted to the specific brain regions affected in PD. Chapter 4 examined the potential mechanisms of CRP40, and suggested that this protein may protect neurons from oxidative stress, maintain energy levels, and mitochondrial homeostasis, with important future implications for a variety of disorders. Finally, Chapter 5 presented compelling evidence for the potential use of CRP40 as a valid biomarker for early detection of PD and monitoring of disease progression. Overall, findings suggest that CRP40 may be a critical target for future breakthroughs in the diagnosis and treatment of PD.</p>"]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Science (PhD)"]},{"key":"dc:title","label":"Title","values":["CATECHOLAMINE-REGULATED PROTEIN 40 IN PARKINSON’S DISEASE"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Gabriele, Joseph","Mishra, Ram","Doering, Laurie"],"dc:contributor.department":["Neuroscience"],"dc:creator":["Lubarda, Jovana"],"dc:date.accessioned":["2014-06-18T17:05:42Z"],"dc:date.available":["2014-06-18T17:05:42Z"],"dc:date.created":["2014-02-04"],"dc:date.issued":["2014-04"],"dc:description.abstract":["<p>Parkinson’s disease (PD) is a complex neurodegenerative movement disorder involving protein misfolding, mitochondrial dysfunction, and oxidative stress. The current dissertation, motivated by a lack of valid biomarkers and sustainable therapies, examined the potential application of a novel target for therapeutics and diagnostics of PD — the multifunctional, heat-shock like protein Catecholamine-Regulated Protein 40 (CRP40). The goal of this program of research was to elucidate further the implications of CRP40 in PD using a variety of molecular biology, bioinformatics, and clinical approaches through integrative collaborations with academia, government, and industry partners to translate scientific findings into real world solutions. Chapters 2 and 3 explored the potential therapeutic use and structure-function relationships of CRP40 through elucidating the smallest functional piece of this protein that was six times smaller, and validating a negative control for these experiments (Heat-Shock Protein 47). These initiatives could eventually lead to a small drug that could cross the blood-brain barrier and be targeted to the specific brain regions affected in PD. Chapter 4 examined the potential mechanisms of CRP40, and suggested that this protein may protect neurons from oxidative stress, maintain energy levels, and mitochondrial homeostasis, with important future implications for a variety of disorders. Finally, Chapter 5 presented compelling evidence for the potential use of CRP40 as a valid biomarker for early detection of PD and monitoring of disease progression. Overall, findings suggest that CRP40 may be a critical target for future breakthroughs in the diagnosis and treatment of PD.</p>"],"dc:description.degree":["Doctor of Science (PhD)"],"dc:identifier.other":["opendissertations/8791","9858","5060668"],"dc:identifier.uri":["http://hdl.handle.net/11375/13959","https://doi.org/10.71548/18778"],"dc:subject":["Catecholamine-regulated protein 40","Parkinson’s disease","movement disorder","protein cloning","oxidative stress","Diagnosis","Medical Biochemistry","Medical Molecular Biology","Nervous System Diseases","Therapeutics"],"dc:title":["CATECHOLAMINE-REGULATED PROTEIN 40 IN PARKINSON’S DISEASE"],"dc:type":["thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:37:30Z"}